responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Disclosures. Joseph V. Pergolizzi, Robert Taylor, Jr, Jo Ann LeQuang, Robert B. Raffa, and
Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended‑release product Joseph V Pergolizzi, Jr,1 Robert Taylor Jr,1 Jo Ann
Pharmaceuticals Inc., Joseph V Pergolizzi Jr. is a consultant/ speaker and/ or researcher for: Inspirion, Mallinckrodt, Collegium, Purdue Pharma LLP, Grunenthal GmhB, Inspirion, ENDO Pharmaceuticals Iroko, DepoMed
Morphine and other opioids are widely used to manage moderate to severe acute pain syndromes, such as pain associated with trauma or postoperative pain, and they have been used to manage chronic pain, even chronic nonmalignant pain. However, recent years have seen a renewed recognition of the potential for overuse, misuse, and abuse of opioids. Therefore, prescribing opioids is...
Since 1986, the pharmacological management of pain was mainly based on the WHO “analgesic ladder”, with very few drugs available. The huge development of the basic knowledge on pain and its therapy, especially in the past 15 years, has made the “guidelines” of WHO obsolete. That’s why, during the presidency of EFIC of one of the authors (GV), an international advisory board was...
Management of moderate to severe chronic low back pain with buprenorphine buccal film using novel bioerodible mucoadhesive technology Joseph V Pergolizzi Jr,1 Robert B Raffa,2,3 Charles Fleischer,1
Acute pain, prevalent as part of postoperative and traumatic pain, is often sub-optimally or inadequately treated. Fixed-dose combination analgesic products that combine a reduced amount of opioid with a nonopioid analgesic such as acetaminophen (paracetamol) in a single tablet offer potential pharmacodynamic and/or pharmacokinetic benefits, and may also result in an opioid...
; Accepted 2 November 2013; Published 5 February 2014 Academic Editor: Giora Pillar Copyright © 2014 Joseph V. Pergolizzi Jr. et al. This is an open access article distributed under the Creative Commons ... patients. Conflict of Interests Joseph V. Pergolizzi Jr. is a consultant for Purdue Pharma, Grünenthal, Endo, Pfizer, INSYS Therapeutics, Baxter, and is a consultant and on the speakers bureau for Lilly USA
2011; Accepted 9 May 2011 Academic Editor: Claudia Valenta Copyright © 2011 Joseph V. Pergolizzi et al. This is an open access article distributed under the Creative Commons Attribution License
Mitigating the risk of opioid abuse through a balanced undergraduate pain medicine curriculum Patricia K Morley-Forster,1 Joseph V Pergolizzi,2–4 Robert Taylor Jr,4 Robert A Axford-Gatley,5 Edward M ... edward M Sellers 3 Department of Anesthesia and Perioperative Medicine, University of w estern Ontario , London, ON , Canada 4 Joseph v Pergolizzi 5 DL Global Partners inc , Toronto, ON , Canada 6 Clinical
Naltrexone extended-release injection: an option for the management of opioid abuse Robert Taylor Jr1, Robert B Raffa2, Joseph V Pergolizzi Jr3,41NEMA Research Inc, Naples, FL, 2Department of ... University School of Medicine , Baltimore, MD , USA 1 Department of Pharmaceutical Sciences, Temple University School of Pharmacy , Philadelphia, PA , USA 2 NeMA Research inc , Naples, FL , USA 3 Joseph v
All patients undergoing bowel resection experience postoperative ileus, a transient cessation of bowel motility that prevents effective transit of intestinal contents or tolerance of oral intake, to varying degrees. An anesthesiologist plays a critical role, not only in the initiation of surgical anesthesia, but also with the selection and transition to effective postoperative...
Fixed-dose combinations at the front line of multimodal pain management: perspective of the nurse-prescriber Joanne O’Brien,1 Joseph V Pergolizzi Jr,2 Mart van de Laar3, Hans-Ulrich Mellinghoff,4
Pergolizzi 0 0 Johns Hopkins University School of Medicine , Baltimore, MD , USA 1 Mercy Hospital Anderson , Cincinnati, Ohio , USA 2 Department of Anesthesia, and Health Research & Policy, Stanford University